Novel mfgl2 antisense plasmid inhibits murine fgl2 expression and ameliorates murine hepatitis virus type 3-induced fulminant hepatitis in BALB/cJ mice

Human Gene Therapy

Volumn 17, Issue 6, 2006, Pages 589-600

  Zhu, Chuanlong ^a   Sun, Yi ^a   Luo, Xiaoping ^a   Yan, Weiming ^a   Xi, Dong ^a   Ning, Qin ^a,b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Tongji Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR; COMPLEMENTARY DNA; FIBRINOGEN LIKE PROTEIN 2; GAMMA INTERFERON; PLASMID DNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE; GENE REPRESSION; GENE SILENCING; IMMUNOHISTOCHEMISTRY; MFGL2 GENE; MOUSE; MURINE HEPATITIS CORONAVIRUS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; VIRUS HEPATITIS;

ANIMALS; CELL LINE; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DNA, ANTISENSE; FIBRINOGEN; GENE EXPRESSION; GENE THERAPY; HEPATITIS, VIRAL, ANIMAL; LIVER; MACROPHAGES; MICE; MICE, INBRED BALB C; MURINE HEPATITIS VIRUS; PLASMIDS; SURVIVAL RATE;

MURINAE; MURINE HEPATITIS VIRUS;

EID: 33745645833     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2006.17.589     Document Type: Article

References (45)

1. BASS, B.L. (2000). Double-stranded RNA as a template for gene silencing. Cell 101, 235-238.
2. BESTOR, T.H. (2000). Gene silencing as threat to the success of gene therapy. J. Clin. Invest. 105, 409-411.
3. CAPLEN, N.J., PARRISH, S., IMANI, F., FIRE, A., and MORGAN, R.A. (2001). Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc. Natl. Acad. Sci. U.S.A. 98, 9742-9747.
4. CHAN, C.W., CHAN, M.W., LIU, M., FUNG, L., COLE, E.H., LEIBOWITZ, J.L., MARSDEN, P.A., CLARK, D.A., and LEVY, G.A. (2002). Kinetic analysis of a unique direct prothrombinase, fgl2, and identification of a serine residue critical for the prothrombinase activity. J. Immunol. 168, 5170-5177.
5. CHENG, V.C., LO, C.M., and LAU, G.K. (2003). Current issues and treatment of fulminant hepatic failure including transplantation in Hong Kong and the Far East. Semin. Liver Dis. 23, 239-250.
6. CHRIST, G.J., DAY, N., SANTIZO, C., SATO, Y., ZHAO, W., SCLAFANI, T., BAKAL, R., SALMAN, M., DAVIES, K., and MELMAN, A. (2004). Intracorporal injection of hSlo cDNA restores erectile capacity in STZ-diabetic F-344 rats in vivo. Am. J. Physiol. Heart Circ. Physiol. 287, H1544-H1553.
7. COLEMAN, W.B. (2003). Mechanisms of human hepatocarcinogenesis. Curr. Mol. Med. 3, 573-588.
8. CORDEIRO, M.F., MEAD, A., ALI, R.R., ALEXANDER, R.A., MURRAY, S., CHEN, C., YORK-DEFALCO, C., DEAN, N.M., SCHULTZ, G.S., and KHAW, P.T. (2003). Novel antisense oligonucleotides targeting TGF-β inhibit in vivo scarring and improve surgical outcome. Gene Ther. 10, 59-71.
9. CROOKE, S.T. (2001). Basic principles of antisense technology. In: Crooke, S.T., ed. Antisense Drug Technology: Principles, Strategies and Applications. (Marcel Dekker, New York) pp. 1-28.
10. DAVE, R.S., and POMERANTZ, R.J. (2003). RNA interference: On the road to an alternate therapeutic strategy! Rev. Med. Virol. 13, 373-385.
11. DING, J.W., NING, Q., LIU, M.F., LAI, A., LEIBOWITZ, J., PELTEKIAN, K.M., COLE, E.H., FUNG, L.S., HOLLOWAY, C., MARSDEN, P.A., YEGER, H., PHILLIPS, M.J., and LEVY, G.A. (1997). Fulminant hepatic failure in murine hepatitis virus strain 3 infection: Tissue-specific expression of a novel fgl2 prothrombinase. J. Virol. 71, 9223-9230.
12. DING, J.W., NING, Q., LIU, M.F., LAI, A., PELTEKIAN, K., FUNG, L., HOLLOWAY, C., YEGER, H., PHILLIPS, M.J., and LEVY, G.A. (1998). Expression of the fgl2 and its protein product (prothrombinase) in tissues during murine hepatitis virus strain-3 (MHV-3) infection. Adv. Exp. Med. Biol. 440, 609-618.
13. FUJIWARA, K., OGATA, I., OHTA, Y., HIRATA, K., OKA, Y., YAMADA, S., SATO, Y., MASAKI, N., and OKA, H. (1988). Intravascular coagulation in acute liver failure in rats and its treatment with antithrombin III. Gut 29, 1103-1108.
14. FUNG, L.S., NEIL, G., LEIBOWITZ, J., COLE, E.H., CHUNG, S., CROW, A., and LEVY, G.A. (1991). Monoclonal antibody analysis of a unique macrophage procoagulant activity induced by murine hepatitis virus strain 3 infection. J. Biol. Chem. 266, 1789-1795.
15. FURLING, D., DOUCET, G., LANGLOIS, M.A., TIMCHENKO, L., BELANGER, E., COSSETTE, L., and PUYMIRAT, J. (2003). Viral vector producing antisense RNA restores myotonic dystrophy myoblast functions. Gene Ther. 10, 795-802.
16. GUIDOTTI, L.G., and CHISARI, F.V. (2001). Noncytolytic control of viral infections by the innate and adaptive immune response. Annu. Rev. Immunol. 19, 65-91.
17. HIGUCHI, H., and GORES, G.J. (2003). Mechanisms of liver injury: An overview. Curr. Mol. Med. 3, 483-490.
18. HONG, F., JARUGA, B., KIM, W.H., RADAEVA, S., EL-ASSAL, O.N., TIAN, Z., NGUYEN, V.A., and GAO, B. (2002). Opposing roles of STAT1 and STAT3 in T cell-mediated hepatitis: Regulation by SOCS. J. Clin. Invest. 110, 1503-1513.
19. HOOFNAGLE, J.H., CARITHERS, R.L., JR., SHAPIRO, C., and ASCHER, N. (1995). Fulminant hepatic failure: Summary of a workshop. Hepatology 21, 240-252.
20. KAKIMI, K., LANE, T.E., WIELAND, S., ASENSIO, V.C., CAMPBELL, I.L., CHISARI, F.V., and GUIDOTTI, L.G. (2001). Blocking chemokine responsive to γ-2/interferon (IFN)-γ inducible protein and monokine induced by IFN-γ activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes. J. Exp. Med. 194, 1755-1766.
21. LEIFELD, L., CHENG, S., RAMAKERS, J., DUMOULIN, F.L., TRAUTWHN, C., SAUERBRUCH, T., and SPENGLER, U. (2002). Imbalanced intrahepatic expression of interleukin 12, interferon γ, and interleukin 10 in fulminant hepatitis B. Hepatology 36, 1001-1008.
22. LIU, M., LEIBOWITZ, J.L., CLARK, D.A., MENDICINO, M., NING, Q., DING, J.W., D'ABREO, C., FUNG, L., MARSDEN, P.A., and LEVY, G.A. (2003). Gene transcription of fgl2 in endothelial cells is controlled by Ets-1 and Oct-1 and requires the presence of both Sp1 and Sp3. Eur. J. Biochem. 270, 2274-2286.
23. LIU, M.F., CHAN, W.Y., MCGILVRAY, I.D., NING, Q., and LEVY, G.A. (2001), Fulminant viral hepatitis: Molecular and cellular basis, and clinical implications. Expert Rev. Mol. Med. 3, 1-19.
24. MARSDEN, P.A., NING, Q., FUNG, L.S., LUO, X., CHEN, Y., MENDICINO, M., GHANEKAR, A., SCOTT, J.A., MILLER, T., CHAN, C.W., CHAN, M.W., HE, W., GORCZYNSKI, R.M., GRANT, D.R., CLARK, D.A., PHILLIPS, M.J., and LEVY, G.A. (2003). The Fgl2/fibroleukin prothrombinase contributes to immunologically- mediated thrombosis in experimental and human viral hepatitis. J. Clin. Invest. 112, 58-66.
25. MCCAFFREY, A.P., MEUSE, L., KARIMI, M., CONTAG, C.H., and KAY, M.A. (2003). A potent and specific morpholino antisense inhibitor of hepatitis C translation in mice. Hepatology 38, 503-508.
26. MOCHIDA, S., OGATA, I., HIRATA, K., OHTA, Y., YAMADA, S., and FUJIWARA, K. (1990). Provocation of massive hepatic necrosis by endotoxin after partial hepatectomy in rats. Gastroenterology 99, 771-777.
27. MONDELLI, M., and EDDLESTON, A.L. (1984). Mechanisms of liver cell injury in acute and chronic hepatitis B. Semin. Liver Dis. 4, 47-58.
28. + T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals. Hum. Gene Then 16, 1065-1074.
29. MOURICH, D.V., and MARSHALL, N.B. (2005). Antisense approaches to immune modulation for transplant and autoimmune diseases. Curr. Opin. Pharmacol. 5, 508-512.
30. NAKAMOTO, Y., and KANEKO, S. (2003). Mechanisms of viral hepatitis induced liver injury. Curr. Mol. Med. 3, 537-544.
31. NING, Q., BROWN, D., PARODO, J., CATTRAL, M., GORCZYNSKI, R., COLE, E., FUNG, L., DING, J.W., LIU, M.F., ROTSTEIN, O., PHILLIPS, M.J., and LEVY, G.A. (1998). Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J. Immunol. 160, 3487-3493.
32. NING, Q., LIU, M., KONGKHAM, P., LAI, M.M., MARSDEN, P.A., TSENG, J., PEREIRA, B., BELYAVSKYI, M., LEIBOWITZ, J., PHILLIPS, M.J., and LEVY, G. (1999). The nucleocapsid protein of murine hepatitis virus type 3 induces transcription of the novel fgl2 prothrombinase gene. J. Biol. Chem. 274, 9930-9936.
33. NING, Q., LAKATOO, S., LIU, M., YANG, W., WANG, Z., PHILLIPS, M.J., and LEVY, G.A. (2003). Induction of prothrombinase fgl2 by the nucleocapsid protein of virulent mouse hepatitis virus is dependent on host hepatic nuclear factor-4α. J. Biol. Chem. 278, 15541-15549.
34. NING, Q., SUN, Y., HAN, M., ZHANG, L., ZHU, C., ZHANG, W., GUO, H., LI, J., YAN, W., GONG, F., CHEN, Z., HE, W., KOSCIK, C., SMITH, R., GORCZYNSKI, R., LEVY, G., and LUO, X. (2005). Role of fibrinogen-like protein 2 prothrombinase/fibroleukin in experimental and human allograft rejection. J. Immunol. 174, 7403-7411.
35. O'GRADY, J.G., and WILLIAMS, R. (1986). Management of acute liver failure. Schweiz Med. Wochenschr. 116, 541-544.
36. PAWLOTSKY, J.M. (2002). Molecular diagnosis of viral hepatitis. Gastroenterology 122, 1554-1568.
37. RAKE, M.O., FLUTE, P.T., PANNELL, G., and WILLIAMS, R. (1970). Intravascular coagulation in acute hepatic necrosis. Lancet 14, 533-537.
38. RHOADS, J. (2003). Natural history and epidemiology of hepatitis C. J. Assoc. Nurses AIDS Care 14(5 Suppl.), 18S-25S.
39. STEPHENSON, M.L., and ZAMECNIK, P.C. (1978). Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc. Natl. Acad. Sci. U.S.A. 75, 285-288.
40. STEVENSON, M. (2004). Therapeutic potential of RNA interference. N. Engl. J. Med. 351, 1772-1777.
41. TAMM, I., DORKEN, B., and HARTMANN, G. (2001). Antisense therapy in oncology: New hope for an old idea? Lancet 358, 489-497.
42. WEISS, B., DAVIDKOVA, G., and ZHOU, L.W. (1999). Antisense RNA gene therapy for studying and modeling biological processes. Cell Mol. Life Sci. 55, 334-358.
43. YACYSHYN, B.R., BOWEN-YACYSHYN, M.B., JEWELL, L., TAMI, J.A., BENNETT, C.F., KISNER, D.L., and SHANAHAN, W.R., Jr. (1998). A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 114, 1133-1142.
44. YIN, X., YUTANI, C., IKEDA, Y., ENJYOJI, K., ISHIBASHI-UEDA, H., YASUDA, S., TSUKAMOTO, Y., NONOGI, H., KANEDA, Y., and KATO, H. (2002). Tissue factor pathway inhibitor gene delivery using HVJ-AVE liposomes markedly reduces restenosis in atherosclerotic arteries. Cardiovasc. Res. 56, 454-463.
45. ZHU, C.L., YAN, W.M., ZHU, F., ZHU, Y.F., XI, D., TIAN, D.Y., LEVY, G.A., LUO, X.P., and NING, Q. (2005). Fibrinogen like protein2/fibroleukin expression and its correlation with disease progression in murine hepatitis virus type 3-induced fulminant hepatitis and in patients with severe viral hepatitis B. World J. Gastroenterol. 11, 6936-6940.